ERBB2 and neoplasm: Antibodies can likewise repress tumour development most effectively when they bind to oncogenic growth factor receptors (e.g., HER2/NEU and EGFR) and draw in macrophage or NK cell-actuating Fc receptors or enact the complement proteins' cascade [9].